000130083 001__ 130083
000130083 005__ 20240122171020.0
000130083 0247_ $$2doi$$a10.1016/j.atherosclerosis.2017.05.013
000130083 0248_ $$2sideral$$a99677
000130083 037__ $$aART-2017-99677
000130083 041__ $$aeng
000130083 100__ $$aMasana, L.
000130083 245__ $$aHow many familial hypercholesterolemia patients are eligible for PCSK9 inhibition?
000130083 260__ $$c2017
000130083 5060_ $$aAccess copy available to the general public$$fUnrestricted
000130083 5203_ $$aBackground and aims Familial hypercholesterolemia (FH) is a high cardiovascular risk condition. Less than 20% of patients achieve the LDL targets. Although PCSK9 inhibitors improve control and reduce cardiovascular events, official recommendations for their use are restrictive. We aim to assess the number of FH patients suitable for PCSK9 inhibition according to the European guidelines. Methods A total of 2685 FH patients, with a minimum follow-up of 6 months, included in the Dyslipidemia Registry of the Spanish Arteriosclerosis Society, were sorted according to the intensity of their lipid-lowering therapy (LLT) and LDL cholesterol levels achieved. The number of patients who met the recommendations for PCSK9 inhibition treatment according to the European Atherosclerosis Society (ESC/EAS), Spanish Arteriosclerosis Society and the European Medicines Agency was calculated. Results In total, 1573 patients were on high-intensity LLT; 607 were on moderate-intensity statins; 82 were on low-intensity LLT, and 423 were neither on statins nor on ezetimibe in the last visit registered. The mean LDL reduction among those on high-intensity LLT was 54%. Ninety-one percent of patients on high-intensity LLT had an LDL below 5.2 mmol/L, 53% below 3.4 mmol/L, and 23% below 2.6 mmol/L. Only 12% of FH patients with cardiovascular disease achieved 1.8 mmol/L. Despite this, only 17% of patients qualified for PCSK9 inhibition according to ESC/EAS guidelines. Conclusions For patients with a condition that exposes them to high cardiovascular risk and who have extreme difficulties in achieving LDL targets, wider access to PCSK9 inhibitor therapy is warranted.
000130083 536__ $$9info:eu-repo/grantAgreement/ES/FIS/PI15-01983
000130083 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttp://creativecommons.org/licenses/by-nc-nd/3.0/es/
000130083 590__ $$a4.467$$b2017
000130083 591__ $$aPERIPHERAL VASCULAR DISEASE$$b9 / 65 = 0.138$$c2017$$dQ1$$eT1
000130083 591__ $$aCARDIAC & CARDIOVASCULAR SYSTEMS$$b34 / 128 = 0.266$$c2017$$dQ2$$eT1
000130083 592__ $$a1.967$$b2017
000130083 593__ $$aCardiology and Cardiovascular Medicine$$c2017$$dQ1
000130083 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/acceptedVersion
000130083 700__ $$aPlana, N.
000130083 700__ $$0(orcid)0000-0002-1894-1621$$aPérez-Calahorra, S.
000130083 700__ $$aIbarretxe, D.
000130083 700__ $$0(orcid)0000-0002-9647-0108$$aLamiquiz-Moneo, I.
000130083 700__ $$aPedro-Botet, J.
000130083 700__ $$aSuárez-Tembra, M.
000130083 700__ $$aValdivielso, P.
000130083 700__ $$aOrtega, E.
000130083 700__ $$0(orcid)0000-0001-7043-0952$$aCiveira, F.$$uUniversidad de Zaragoza
000130083 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000130083 773__ $$g262 (2017), 107-112$$pAtherosclerosis$$tAtherosclerosis$$x0021-9150
000130083 8564_ $$s1115972$$uhttps://zaguan.unizar.es/record/130083/files/texto_completo.pdf$$yPostprint
000130083 8564_ $$s1794559$$uhttps://zaguan.unizar.es/record/130083/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint
000130083 909CO $$ooai:zaguan.unizar.es:130083$$particulos$$pdriver
000130083 951__ $$a2024-01-22-15:26:31
000130083 980__ $$aARTICLE